Search results
Showing 46 to 60 of 65 results for diabetic foot
Which risk stratification tools can be used to predict the likelihood of Charcot arthropathy?
applicable) Source guidance details Comes from guidance Diabetic foot problems: prevention and management Number NG19 Date
sequelae. Source guidance details Comes from guidance Diabetic foot problems: prevention and management Number NG19 Date
Summary of the evidence on antimicrobial prescribing: delafloxacin
This indicator covers the proportion of children and young people aged 12 to 18 years with type 2 diabetes who have a record of a foot examination in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who have a record of a foot examination in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Type 2 diabetes prevention: population and community-level interventions (PH35)
This guideline covers preventing type 2 diabetes in adult populations and communities who are at high risk. It aims to promote a healthy diet and physical activity at community and population level, and recommends how to tailor services for people in ethnic communities and other groups who are particularly at risk of type 2 diabetes.
Evidence-based recommendations on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus). This involves replacing damaged cartilage with an artificial (synthetic) implant.
View recommendations for HTG627Show all sections
Evidence-based recommendations on the VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal.
Diabetic foot problems: Inpatient management of diabetic foot problems (CG119)
This guidance has been updated and replaced by NICE guideline NG19.
higher risk of cardiovascular events and foot problems such as diabetic neuropathy (nerve damage or degeneration),...
This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.
We have moved Medical technologies guidance 66 to become HealthTech guidance 615. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This advice has been updated and replaced by NICE Healthtech guidance 615.
UrgoStart for treating diabetic foot ulcers and leg ulcers (MTG42)
We have moved Medical technologies guidance 42 to become HealthTech guidance 502. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.